Alkem Laboratories says it is aiming to replicate its success in small-molecule generics with biosimilars, after announcing the approval in India of a rival to Eli Lilly’s Forteo (teriparatide) osteoporosis treatment. The approval came through Alkem’s Enzene Biosciences subsidiary.
Announcing the marketing authorization obtained from the Drug Controller General of India for teriparatide, Alkem said that “according to company sources the clinical trial conducted for Enzene's teriparatide is one of the most comprehensive trials for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?